Can-Fite BioPharma Files 6-K Report

Ticker: CANF · Form: 6-K · Filed: Mar 20, 2025 · CIK: 1536196

Can-Fite Biopharma LTD. 6-K Filing Summary
FieldDetail
CompanyCan-Fite Biopharma LTD. (CANF)
Form Type6-K
Filed DateMar 20, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-k, disclosure

TL;DR

Can-Fite BioPharma filed a 6-K on 3/20/25, updating its SEC filings.

AI Summary

On March 20, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating a press release by reference into its existing SEC registration statements. This filing relates to its ongoing operations as a foreign private issuer.

Why It Matters

This filing provides an update on Can-Fite BioPharma's regulatory status and incorporates information into its existing SEC filings, which is important for investors tracking the company's disclosures.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that incorporates previous information and does not appear to contain new material financial or operational news.

Key Players & Entities

FAQ

What type of SEC filing is this?

This is a Form 6-K, a Report of Foreign Private Issuer.

Who is the filer of this report?

The filer is Can-Fite BioPharma Ltd.

What is the filing date?

The filing date is March 20, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 26 Ben Gurion Street, Ramat Gan, 5257346, Israel.

What is being incorporated by reference into the registration statements?

The first paragraph of the press release attached as Exhibit 99.1 is being incorporated by reference.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding Can-Fite BioPharma Ltd. (CANF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing